CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04081324
NCT04081324Phase 1Completed
CompareCT.gov

Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Chinese Subjects

Eli Lilly and Company·interventional·Posted Sep 9, 2019·Updated Jul 1, 2021

In Brief

A Phase 1 clinical trial evaluating Lasmiditan and Placebo for Healthy. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This is a study of lasmiditan in healthy Chinese participants. The purposes are: * To evaluate the safety of lasmiditan * To learn more about how the body processes lasmiditan The study will last up to 50 days for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 9, 2019
Enrollment StartNov 13, 2019
Primary CompletionJun 15, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.8 years ago

Interventions

Lasmiditandrug

Administered orally

Placebodrug

Administered orally